METHOD FOR DETERMINING REMITTANCE IN A PATIENT SUFFERING RHEUMATOID ARTHRITIS WITH UNDERLYING 5-YEAR THERAPY OF BASIC ANTI-INFLAMMATORY PREPARATIONS OR BASIC ANTI-INFLAMMATORY PREPARATIONS IN COMBINATION WITH GENETICALLY ENGINEERED BIOLOGICAL PREPARATIONS AND ACCOMPANYING COMORBID ANXIETY-DEPRESSIVE DISORDER Russian patent published in 2019 - IPC A61B5/00 

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to rheumatology. A set of the following parameters is evaluated: patient's sex; glucocorticoids intake duration; DAS28 before therapy; presence of IHD after 5-year basic anti-inflammatory therapy RA; monotherapy with basic anti-inflammatory drugs (BAID) for 5 years or complex therapy BAID in combination with genetically engineered biological preparations; presence of maximum destruction of joints after 5-year basic anti-inflammatory therapy of RA in the form of III or IV X-ray stage of RA and / or aseptic necrosis of bones; availability of ADD after 5-year basic anti-inflammatory therapy RA. Obtained data are processed with the help of original equation and based on the obtained result, conclusion is made on achieving RA remission in this category of patients.

EFFECT: method enables objectively establishing the fact of achieving remission of RA in patients with accompanying ADD.

1 cl, 1 dwg, 5 tbl, 2 ex